Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse

Richardson, Stacey, Hill, Rebecca M, Kui, Christopher, Lindsey, Janet C, Grabovksa, Yura, Keeling, Claire, Pease, Louise, Bashton, Matthew, Crosier, Stephen, Vinci, Maria, André, Nicolas, Figarella-Branger, Dominique, Hansford, Jordan R, Lastowska, Maria, Zakrzewski, Krzysztof, Jorgensen, Mette, Pickles, Jessica C, Taylor, Michael D, Pfister, Stefan M, Wharton, Stephen B, Pizer, Barry, Michalski, Antony, Joshi, Abhijit, Jacques, Thomas S, Hicks, Debbie, Schwalbe, Edward C, Williamson, Daniel, Ramaswamy, Vijay, Bailey, Simon and Clifford, Steven C (2021) Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. Neuro-Oncology. noab178. ISSN 1522-8517 (In Press)

[img] Text
noab178.pdf - Accepted Version
Restricted to Repository staff only until 17 July 2022.

Download (983kB) | Request a copy
Official URL: https://doi.org/10.1093/neuonc/noab178


Background: <5% of medulloblastoma patients survive following failure of contemporary radiation-based therapies. Understanding the molecular drivers of medulloblastoma relapse (rMB) will be essential to improve outcomes. Initial genome-wide investigations suggested significant genetic divergence of the relapsed disease.
Methods: We undertook large-scale integrated characterization of the molecular features of rMB - molecular subgroup, novel subtypes, copy number variation (CNV) and driver gene mutation. 119 rMBs were assessed in comparison with their paired diagnostic samples (n=107), alongside an independent reference cohort sampled at diagnosis (n=282). rMB events were investigated for association with outcome post-relapse in clinically-annotated patients (n=54).
Results: Significant genetic evolution occurred over disease-course; 40% of putative rMB drivers emerged at relapse and differed significantly between molecular subgroups. MBSHH Non-infant displayed significantly more chromosomal CNVs at relapse (TP53 mutation-associated). Relapsed MBGroup4 demonstrated the greatest genetic divergence, enriched for targetable (e.g. CDK amplifications) and novel (e.g. USH2A mutations) events. Importantly, many hallmark features of medulloblastoma were stable over time; novel subtypes (>90% of tumors) and established genetic drivers (e.g. SHH/WNT/P53 mutations; 60% of rMB events) were maintained from diagnosis. Critically, acquired and maintained rMB events converged on targetable pathways which were significantly enriched at relapse (e.g. DNA damage-signaling) and specific events (e.g. 3p loss) predicted survival post-relapse.
Conclusions: rMB is defined by the emergence of novel events and pathways, in concert with selective maintenance of established genetic drivers. Together, these define the actionable genetic landscape of rMB and provide a basis for improved clinical management and development of stratified therapeutics, across disease-course.

Item Type: Article
Uncontrolled Keywords: Medulloblastoma, Relapse, Drivers, Genomics, Subgroups
Subjects: A300 Clinical Medicine
C100 Biology
C400 Genetics
Department: Faculties > Health and Life Sciences > Applied Sciences
Depositing User: John Coen
Date Deposited: 27 Jul 2021 10:08
Last Modified: 31 Jul 2021 10:02
URI: http://nrl.northumbria.ac.uk/id/eprint/46763

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics